Kite Pharma

Overview

Gilead subsidiary and CAR-T cell therapy manufacturer; its Amsterdam commercial facility producing 4,000 doses/year with ~1,000 staff is cited as evidence that current autologous cell therapy manufacturing is too labor-intensive to be a viable industry. Kite Pharma's commercial CAR-T manufacturing facility in Amsterdam is sized for 4,000 doses per year with a headcount of just under 1,000, yielding approximately four doses per operator per year — a ratio Matthew Dy identifies as fundamentally unsustainable for commercial industry scale and as the central driver of prohibitive cost of goods blocking large-pharma engagement. (Segment 8 (35:00-39:50))